With a consistent decline in share price and EPS, BGI Genomi...
With a consistent decline in share price and EPS, BGI Genomics' investor sentiment is negative. Market likely factored in falling EPS with a high PE ratio at 79.62. Despite 'buy when blood's on the streets' philosophy, investors should consider the company's 3 warning signs, of which 2 are serious.
Investors Three-year Losses Continue as BGI Genomics (SZSE:300676) Dips a Further 9.0% This Week, Earnings Continue to Decline
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment